- Report
- March 2025
- 427 Pages
Global
From €5201EUR$5,450USD£4,358GBP
- Report
- February 2025
- 150 Pages
Global
From €4629EUR$4,850USD£3,878GBP
- Report
- December 2024
- 150 Pages
Global
From €4629EUR$4,850USD£3,878GBP
- Report
- November 2024
- 150 Pages
Global
From €4629EUR$4,850USD£3,878GBP
- Report
- November 2024
- 150 Pages
Global
From €4629EUR$4,850USD£3,878GBP
- Report
- September 2024
- 150 Pages
Global
From €4629EUR$4,850USD£3,878GBP
- Report
- February 2025
- 120 Pages
Global
From €2376EUR$2,490USD£1,991GBP
- Report
- August 2024
- 260 Pages
Global
From €2186EUR$2,290USD£1,831GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- December 2024
- 175 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- August 2024
- 175 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- July 2024
- 175 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- July 2024
- 175 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- March 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- March 2025
- 175 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP

The Targeted Therapies market within the context of Genomics is focused on the development of treatments that target specific genetic mutations or pathways. These therapies are designed to be more effective and have fewer side effects than traditional treatments. Genomics has enabled the development of personalized treatments that are tailored to the individual patient's genetic makeup. This has allowed for the development of drugs that target specific mutations or pathways, leading to more effective treatments.
The Targeted Therapies market is a rapidly growing field, with many companies investing in research and development. Companies such as Gilead Sciences, Novartis, and AstraZeneca are leading the way in the development of targeted therapies. Other companies such as Merck, Pfizer, and Roche are also investing in the development of targeted therapies. Show Less Read more